Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VSTM
SellHot AirVerastem, Inc. · Healthcare · United States · $654M · Avg Vol: $17M/d
COMPANY DESCRIPTION
Verastem Oncology is a biopharmaceutical company focused on developing and commercializing novel, small-molecule drugs to treat RAS-pathway-driven cancers. The company's lead development candidate, a combination of a RAF/MEK inhibitor and a FAK inhibitor, targets highly resistant solid tumors such as low-grade serous ovarian cancer. Its competitive advantage lies in its unique combination therapy approach, which aims to overcome therapeutic resistance mechanisms that limit standard oncology treatments.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.6M | 0 | 10.0M | 30.9M | 128.4% | 87.5M | 116.4M | 181.1M | 142.1% |
| EPS | -0.87 | -1.14 | -3.66 | -3.02 | — | -2.44 | -1.80 | -0.75 | — |
| Shares | 87.9M | 87.9M | 44.8M | 77.7M | -11.5% | 90.6M | — | — | — |
| Debt | 27.1M | 41.6M | 42.3M | 87.2M | 47.7% | 84.3M | — | — | — |
| Equity | 47.4M | 57.4M | -28.9M | 57.2M | 6.5% | — | — | — | — |
| Op CF | -63.7M | -86.5M | -104.8M | -137.5M | — | -162.2M | — | — | — |
| Inv CF | 66.2M | -44.4M | 60.0M | -9.6M | — | — | — | — | — |
| Fin CF | 51.8M | 134.2M | 54.8M | 263.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VSTM are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VSTM | Verastem, Inc.(you) | $654M | 27 | Sell |
| CTNM | Contineum Therapeutics, Inc. | $641M | 30 | Sell |
| DRUG.CN | Bright Minds Biosciences Inc. | $698M | 24 | Sell |
| CBIO | Crescent Biopharma, Inc. | $659M | 22 | Sell |
| TECX | Tectonic Therapeutic, Inc. | $696M | 23 | Sell |
| SGMT | Sagimet Biosciences Inc. | $656M | 32 | Sell |
| ASMB | Assembly Biosciences, Inc. | $694M | 31 | Sell |
| AURA | Aura Biosciences, Inc. | $767M | 24 | Sell |
| FDMT | 4D Molecular Therapeutics, Inc. | $810M | 25 | Sell |
| NVCT | Nuvectis Pharma, Inc. | $775M | 24 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%